- ISIN
- US29479A1088
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Jul 16, 2021
Highlights
- Market Cap
- $4.59B
- Enterprise Value
- $4.59B
- EPS (TTM)
- -$0.96
- Gross Profit (TTM)
- -$743.00K
- EBITDA (TTM)
- -$279.47M
- Year Range
- $1.21 - $24.28
- Target Price
- $13.60
- ROA (TTM)
- -60.06%
- ROE (TTM)
- -70.39%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ERAS Performance Chart
Erasca, Inc. (ERAS) is up 305.4% since the beginning of the year. At $15 per share, ERAS is trading 37.9% below its 52-week high of $24.
Loading charts...
Returns By Period
Erasca, Inc. (ERAS) has returned 305.38% so far this year and 1,000.73% over the past 12 months.
Erasca, Inc.
- 1D
- 10.31%
- 1M
- 34.16%
- YTD
- 305.38%
- 6M
- 313.15%
- 1Y
- 1,000.73%
- 3Y*
- 77.86%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ERAS Monthly Returns History
Based on dividend-adjusted daily data since Jul 16, 2021, ERAS's average daily return is +0.14%, while the average monthly return is +3.24%. At this rate, an investment would double in approximately 1.8 years.
Historically, 45% of months were positive and 55% were negative. The best month was Jan 2026 with a return of +182.5%, while the worst month was Dec 2022 at -42.9%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 7 months.
On a daily basis, ERAS closed higher 48% of trading days. The best single day was Jan 7, 2026 with a return of +42.4%, while the worst single day was Apr 28, 2026 at -48.3%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 182.53% | 29.97% | 18.45% | -34.18% | 20.56% | 17.45% | 305.38% | ||||||
| 2025 | -24.70% | -27.51% | 0.00% | 6.57% | -4.11% | -9.29% | 11.42% | 10.95% | 38.85% | 11.01% | 30.99% | 17.35% | 48.21% |
| 2024 | -21.60% | 42.51% | -13.45% | -2.43% | 25.37% | -6.35% | 33.47% | -8.25% | -5.54% | -5.13% | 10.42% | -12.24% | 17.84% |
| 2023 | -7.19% | -10.00% | -16.39% | -8.31% | -1.81% | 1.85% | -4.35% | -1.89% | -23.94% | 17.26% | -26.41% | 25.29% | -50.58% |
| 2022 | -23.94% | 4.64% | -30.65% | -15.35% | -25.55% | 2.77% | 35.37% | 19.63% | -13.53% | 4.74% | -7.59% | -42.91% | -72.34% |
| 2021 | 32.08% | 13.86% | -11.25% | -6.79% | -28.36% | 9.95% | -2.01% |
Benchmark Metrics
Erasca, Inc. has an annualized alpha of 18.77%, beta of 1.37, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since July 16, 2021.
- This stock participated in 134.21% of S&P 500 Index downside but only 85.58% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 18.77%
- Beta
- 1.37
- R²
- 0.08
- Upside Capture
- 85.58%
- Downside Capture
- 134.21%
Return for Risk
Risk / Return Rank
ERAS ranks 99 for risk / return — in the top 99% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Erasca, Inc. (ERAS) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ERAS | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +7.65 | ||
| Sortino ratioReturn per unit of downside risk | +1.95 | ||
| Omega ratioGain probability vs. loss probability | 1.76 | 1.37 | +0.39 |
| Calmar ratioReturn relative to maximum drawdown | 17.01 | 2.78 | +14.22 |
| Martin ratioReturn relative to average drawdown | 51.62 | 12.44 | +39.18 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Erasca, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Erasca, Inc. was 95.65%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Erasca, Inc. drawdown is 38.04%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -95.65%Apr 2025 | 3y 7mo | — | 4y 9moSep 2021 - now |
2021 pullback2021 | -8.89%Aug 2021 | 8d | 7d | 15dAug 2021 - Aug 2021 |
2021 pullback2021 | -8.19%Aug 2021 | 0s | 7d | 7dAug 2021 - Aug 2021 |
2021 pullback2021 | -5.75%Jul 2021 | 3d | 2d | 5dJul 2021 - Jul 2021 |
2021 pullback2021 | -4.39%Sep 2021 | 0s | 1d | 1dSep 2021 - Sep 2021 |
Drawdown Indicators
| ERAS | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -95.65% | -56.78% | -38.87% |
Max Drawdown (1Y)Largest decline over 1 year | -59.46% | -9.10% | -50.36% |
Max Drawdown (3Y)Largest decline over 3 years | -67.68% | -18.90% | -48.78% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -38.04% | -1.80% | -36.24% |
Average DrawdownAverage peak-to-trough decline | -74.53% | -10.71% | -63.82% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.55% | 2.03% | +17.52% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Erasca, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Erasca, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ERAS in comparison with other companies in the Biotechnology industry. Currently, ERAS has a P/B value of 11.7. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ERAS
Add Erasca, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ERAS